公开(公告)号：WO1996036340A1

公开(公告)日：1996-11-21

申请号：PCT/US1996007074

申请日：1996-05-16

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  LI, Luk, C. ,  PEC, Edward, A. ,  PARASRAMPURIA, Jagdish

IPC: A61K31/59

CPC classification number: A61K31/593 ,  A61K9/0019 ,  A61K47/22 ,  A61K47/26

Abstract: 1 alpha ,25-dihydroxycholecalciferol is a naturally occurring form of Vitamin D3. Vitamin D3 is converted to 1 alpha , 25-dihydroxycholecalciferol in the liver and kidney before it acts to stimulate intestinal calcium and phosphorous absorption. Parenteral solutions of 1 alpha , 25-dihydroxycholecalciferol are suitable for replacement therapy.

Abstract translation: 1α，25-二羟基胆钙化甾醇是天然存在的维生素D3形式。 维生素D3在肝和肾中转化为1α，25-二羟基胆钙化甾醇，然后才能刺激肠钙和磷吸收。 1α，25-二羟基胆钙化醇的肠胃外溶液适用于替代疗法。

公开(公告)号：EP1073467B1

公开(公告)日：2004-09-15

申请号：EP99914970.1

申请日：1999-03-22

Applicant: ABBOTT LABORATORIES

Inventor： LI, Lukchiu ,  PEC, Edward, A. ,  ROBINSON, Daniel, H. ,  STEPHENS, Dennis, A. ,  JANTZI, Kathee ,  MAY, Thomas, B. ,  OBERDIER, John, P.

IPC: A61K47/10 ,  A61K31/59

CPC classification number: A61K9/0019 ,  A61K47/10

Abstract: Stable pharmaceutical formulations of a therapeutic agent, a low molecular weight alcohol and a glycol derivative are disclosed. Preferred formulations include 19-nor-1 alpha ,3 beta ,25-trihydroxy-9,10-secoergosta-5,7(E),22(E)-triene.

公开(公告)号：EP1073467A2

公开(公告)日：2001-02-07

申请号：EP99914970.1

申请日：1999-03-22

Applicant: ABBOTT LABORATORIES

Inventor： LI, Lukchiu ,  PEC, Edward, A. ,  ROBINSON, Daniel, H. ,  STEPHENS, Dennis, A. ,  JANTZI, Kathee ,  MAY, Thomas, B. ,  OBERDIER, John, P.

IPC: A61K47/10 ,  A61K31/59

CPC classification number: A61K9/0019 ,  A61K47/10

Abstract: Stable pharmaceutical formulations of a therapeutic agent, a low molecular weight alcohol and a glycol derivative are disclosed. Preferred formulations include 19-nor-1α,3β,25-trihydroxy-9,10-secoergosta-5,7(E),22(E)-triene.